Tilidine does not affect human sphincter of Oddi motility—a randomized, controlled study

Abstract

Aim: To investigate the effects of intravenous pentazocine and tilidine on sphincter of Oddi motility. Methods: Twenty patients with suspected sphincter of Oddi dysfunction were enrolled in a prospective, double‐blind study. Sphincter of Oddi motility was assessed by means of endoscopic manometry after injection of 0.9% saline, as well as after randomized dosing with either 30 mg pentazocine i.v. (n = 10) or 50 mg tilidine i.v. (n = 10). Results: Pentazocine significantly increased the sphincter of Oddi baseline pressure from 32 ± 21 mmHg (saline) to 41 ± 19 mmHg (P = 0.002), whereas tilidine did not alter the sphincter baseline pressure (34 ± 15 mmHg saline vs. 36 ± 16 mmHg tilidine, P = 0.16). Furthermore, pentazocine increased the phasic sphincter contraction amplitude (108 ± 16 mmHg saline vs. 121 ± 18 mmHg pentazocine, P = 0.004), but tilidine was without any effect (125 ± 24 mmHg saline vs. 125 ± 21 mmHg tilidine, P = 0.93). The phasic sphincter of Oddi contraction frequency and duration were not influenced either by pentazocine or by tilidine. Conclusion: In contrast to 30 mg of pentazocine, 50 mg of tilidine does not affect sphincter of Oddi motility. Therefore, tilidine can be used during endoscopic manometry and for analgesia in pancreatobiliary disease.